| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 102.2 | 103.7 |
| Profit before tax | -14.1 | 0.3 |
| Net income | -14.2 | -0.2 |
| EPS (diluted, $ a share) | $-0.28 | $0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -1.4% |
|---|---|
| Operating margin | -13.3% |
10-Q filed with the SEC, NASDAQ: IMCR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Immunocore Holdings plc: key numbers
- Share price
- $28.88Close, Nov 16
- Market cap
- $1.49B
- Shares outstanding
- 51.68MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Immunocore Holdings plc
All →Immunocore Holdings Financial Results
Immunocore reported Q3 2026 financial results with KIMMTRAK net revenues of $102.2 million and a net loss of $14.2 million. The company highlighted the completion of target enrollment for its Phase 3 TEBE-AM trial in cutaneous melanoma and the first patient dosed in its autoimmune program for type 1 diabetes.
- Term
- Q3 2026
“Nearly five years after launch, KIMMTRAK remains the proven standard of care in HLA-A*02:01+ metastatic uveal melanoma. With TEBE-AM fully enrolled and data expected in the second quarter of 2027, we are advancing our mission to bring this therapy to even more patients.”
Bahija Jallal, CEO of Immunocore
“Recently, our platform delivered two significant firsts: what we believe is the first data demonstrating clinical activity and a manageable safety profile with the combination of two T cell engagers in a solid tumor, and the first patient dosed in our tissue-specific autoimmune program for type 1 diabetes.”
Bahija Jallal, CEO of Immunocore
Immunocore Holdings Business Update
Immunocore has achieved its target enrollment of 540 patients in the Phase 3 TEBE-AM clinical trial evaluating tebentafusp (KIMMTRAK) for the treatment of advanced melanoma. The trial is a registrational study, and the company expects to report topline overall survival data as early as the end of 2026.